ClinicalTrials.gg
RecruitingNCT05865379BUSTON-01Updated Oct 29, 2026

Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease

An interventional study of BUFY01 eye drops in single-dose containers and SVS20 eye drops in single-dose containers in Dry Eye Disease, sponsored by TRB Chemedica International SA. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by TRB Chemedica International SA · Not applicable, Interventional, and Treatment

Updated Oct 29, 2026First site in BelgiumStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Dry Eye Syndromes with a site in France — 13 open to participants now, 14 under way, none of them phase 3. Dry Eye Syndromes · France.

Planned enrollment
21st of 40
80 · median 81
Started
2026
with 5 others
No phase
28 of 47
9 open now
Primary completion
2027-04
later than 7 of 13 live
Registered
33rd of 47
by date
Lead sponsor
2 of 47
TRB Chemedica International SA

Among the 47 studies in Dry Eye Syndromes with a site in France, this one is the 21st largest by planned enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2026, is one of 28 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 33rd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

13 of the 47 studies in Dry Eye Syndromes with a site in France are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Dry Eye Syndromes with a site in France, or all of them as a file.
02

Study summary

The goal of this interventional investigation is to compare BUFY01 with SVS20 in the treatment of patients with dry eye disease. The main questions it aims to answer are:

  • Is BUFY01 non-inferior to SVS20 in terms of signs of DED?
  • Is BUFY01 non-inferior to SVS20 in terms of symptoms of DED?

Participants will be asked to:

  • Visit the trial site at 4 different timepoints
  • Use the allocated study treatment everyday until the end of the study (during 3 months)
  • Be examined by the investigator
  • Complete several questionnaires
  • Return unused study treatment.

Researchers will compare BUFY01 to SVS20 to see if both study treatments provide similar effects on signs and symptoms of the disease, together with comparable safety.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 3-month documented history of bilateral dry eye syndrome needing artificial tears;
  • At least one eye with Oxford score ≥ 4 and ≤ 9;
  • At least one objective sign of tear deficiency (in at least one eligible eye);
  • Having a health insurance.

Exclusion criteria

Exclusion Criteria includes:

  • Wear of contact lenses starting within the last 2 months;
  • Best-corrected visual acuity (BCVA) > 1.00;
  • Severe DED with one of the listed conditions:
  • Severe blepharitis;
  • Seasonal allergy;
  • Any issues of the ocular surface not related to DED;
  • History of ocular trauma, infection or inflammation not related to DED;
  • History of ocular surgery, including laser surgery;
  • Unstable glaucoma;
  • Use of artificial tears with preservative within the last 2 weeks;
  • Systemic (enteral or parenteral) or local (topical) use of one of the listed medications:
  • Known to any constituent of the study treatments;
  • Pregnancy or breastfeeding;
  • Participation in another clinical study within the last 90 days;
  • Legally restricted autonomy, freedom of decision and action.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    BUFY01

    0.18% Sodium Hyaluronate (trometamol buffer) in single-dose containers of 0.3 mL

    Device: BUFY01 eye drops in single-dose containers

  • Active comparator
    SVS20

    0.18% Sodium Hyaluronate (phosphate buffer) in single-dose containers of 0.3 mL

    Device: SVS20 eye drops in single-dose containers

Interventions

  • DeviceBUFY01 eye drops in single-dose containers

    1 to 2 drops in each eye, as often as needed

  • DeviceSVS20 eye drops in single-dose containers

    1 to 2 drops in each eye, as often as needed

06

What researchers measure

Primary outcomes

  1. Signs

    Change from baseline in Oxford score (0-15, a higher score meaning a worse outcome)

    Time frame: Day 28

Secondary outcomes

  1. Symptoms

    Change from baseline in Ocular Surface Disease Index

    Time frame: Day 28

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2027, 6 months after the start.

Of 115 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 6 months is below that.

Counting every sponsor, half of 314 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2023
First posted
May 18, 2023
StartActual
Oct 26, 2026was Aug 2026
Primary completionEst.
Apr 2027
CompletionEst.
Jun 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Belgium
Show site
  • UZ Leuven · Leuven, Belgium
Sep 29, 2026
Start date
Aug 2026→Oct 26, 2026 (actual)
moved 2 times, Sep 29, 2026 – Oct 29, 2026
Show all 2 updates
  1. Oct 29, 2026
    Start date Sep 2026→Oct 26, 2026 (now actual)
    + 1 other change: verification date
  2. Sep 29, 2026
    1 site added — first site in Belgium
    Show site
    • UZ Leuven · Leuven, Belgium
    Start date Aug 2026→Sep 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05865379
Lead sponsor
TRB Chemedica International SA
Responsible party
Sponsor
First posted
May 18, 2023
Start date
Oct 26, 2026
Primary completion
Apr 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion